AstraZeneca, GSK & partners will source 225GWh of renewable power in China, cutting emissions by 250,000 tonnes – equal to ...

Pre-specified interim analysis of Phase 3 PIVOT-PO clinical trial of tebipenem HBr in complicated urinary tract infection (cUTI) is expected to ...

GSK remains on fairly stable financial footing, with a debt/EBITDA ratio of 2.8 at the end of 2024 and Haleon taking on close to GBP 10 billion of GSK's debt in the 2022 divestment. With the improving ...

The CDC has rescheduled a key advisory committee meeting on vaccine experts to April following a delay in February, a week ...

We suggest that investors who own GSK's stock remain invested for now, considering its sales and profits are expected to continue improving in the coming years.

Stocks opened higher on Wednesday ahead of the Federal Reserve’s interest rate announcement at 2 p.m., which will be followed ...

In work conducted by Jining Medical University investigators, synthesis and optimization of a previously reported ...

Biopharma deal activity climbed in early 2025, reaching $37.38 billion in the first two months, up from $35.66 billion a year ago. February saw $8.76 billion in deals, down 69% from January’s $28.63 ...

The U.S. Food and Drug Administration (FDA) has issued its recommendations to vaccine makers on which virus strains to select when manufacturing influenza (flu) vaccines for the 2025-2026 U.S. flu ...

GSK (NYSE:GSK) shares rose for seven straight sessions, as the stock ended 0.7% higher at $40.32 on Monday. The pharmaceutical giant gained over 6.5% in the preceding six sessions. The stock has ...

GSK and Vertex Pharmaceuticals ... s actual appearance on a panel discussion about women’s health at the SXSW conference over the weekend. A detailed post from Regeneron lists several areas ...